Neuroendocrine prostate cancer is one of the most aggressive forms of the disease and remains particularly difficult to treat. A new Oncogene study has identified a possible mechanism that helps these tumours suppress the immune response, centred on a molecule called Neuromedin U, or NMU. In mouse models of neuroendocrine prostate cancer, the researchers found […]
CAR-T therapy has transformed some blood cancers, but solid tumors remain much more difficult. One major problem is tumor heterogeneity: not every cancer cell expresses the same target, and tumours can change over time. A new preclinical study published in Cancer Immunology Research describes a way to make CAR-T cells more adaptable. The researchers created […]
B7-H3 has become one of the most interesting targets in advanced prostate cancer, especially for antibody-drug conjugates and other targeted treatments. A new Cancer Discovery study suggests that B7-H3 may not simply sit on the surface of tumour cells: it may actively help the cancer suppress the immune system and resist treatment. The researchers found […]
A new phase 2 trial will test JNJ-101556143, also known as HLD-0915, in men with metastatic prostate cancer that has become resistant to androgen-pathway treatment. The study plans to enrol about 100 patients and will evaluate whether the drug can produce objective tumour responses, making this a clear step beyond the earlier dose-finding programme. JNJ-101556143 […]
A new first-in-human phase 1 trial, has been posted for JUR-003 in metastatic prostate cancer. The study plans to enrol up to 210 patients and includes dose-escalation and dose-expansion cohorts in mCRPC, metastatic hormone-sensitive prostate cancer (mHSPC) and oligometastatic disease. JUR-003 will be given intravenously, with the initial goals of defining safety, pharmacokinetics and a […]
A new 2026 review proposes an interesting idea: bipolar androgen therapy (BAT) may help make prostate cancer more sensitive to PARP inhibitors, even in some tumours that do not carry the classic BRCA1/2 mutations usually associated with strong PARP responses. BAT exposes prostate cancer cells to rapid swings between very high and very low testosterone […]
We already discussed ENV105 (carotuximab) in a previous ProstateWarriors article, when the safety lead-in of its phase 2 trial in metastatic castration-resistant prostate cancer was completed. Since then, the programme has produced its first meaningful efficacy signal, making it worth revisiting. ENV105 targets CD105, a protein that appears to become more active as prostate cancer […]
A new preclinical study published in Cancer Research has identified a possible way to attack prostate cancer that has become resistant to castration and enzalutamide. The work focuses on BUB1B, a protein involved in controlling cell division, and CENP-E, one of the proteins it helps regulate. When researchers lowered BUB1B levels, resistant prostate cancer cells […]
An inexpensive antifungal drug that has been used for decades is now being tested as a prostate cancer treatment. The phase 2 TerbinaPro trial is evaluating terbinafine in men whose prostate cancer has returned biochemically after previous treatment. Behind this unusual drug-repurposing trial lies an intriguing discovery about how prostate cancer produces cholesterol. The target […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Summer is over, research publishing has picked up again, and this week we have plenty of interesting information to read! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the […]